Genetic Alliance UK works with, and accepts sponsorship, grants, fees for service and funding from pharmaceutical companies when this is in the interests of people affected by rare, genetic and undiagnosed conditions.
This document should be read in conjunction with our Ethical Collaboration Policy. We will also consider requests to support company activities, including patient participation in company activities, provided the request is compliant with the terms of this policy.
In the year 2019-20, Genetic Alliance UK was forced to accept an usually high proportion of income from companies, with the proportion breaking 50% for the first time. This was partially due to a reduction of other sources of income and partially due to extra support from companies to enable Genetic Alliance UK to support its members through the Covid-19 crisis.
From April 2021 forward, Genetic Alliance UK will seek to reduce the total proportion of our annual income received from pharmaceutical and biotechnology companies annually until it reaches 30% of our total annual income.
In working with companies, we will maintain our independence and integrity at all times:
Updated October 2021.